Abstract: The present invention relates generally to compositions, methods and kits for detection of a molecule of interest. The present invention is based, at least in part, on the design of nucleic acid oligonucleotides such that they can be used as molecular building blocks which can be assembled (polymerized) to form a dsDNA polymerization product which can be detected and further, can be disassembled (depolymerized) such that the polymerization product is no longer detectable. The invention can be performed multiple times on the same cell population, and is therefore useful for highly sensitive in situ detection of multiple biomarkers.

Abstract: The present invention relates generally to compositions, methods and kits for detection of a molecule of interest. The present invention is based, at least in part, on the design of nucleic acid oligonucleotides such that they can be used as molecular building blocks which can be assembled (polymerized) to form a dsDNA polymerization product which can be detected and further, can be disassembled (depolymerized) such that the polymerization product is no longer detectable. The invention can be performed multiple times on the same cell population, and is therefore useful for highly sensitive in situ detection of multiple biomarkers.

Abstract: The present invention relates generally to compositions, methods and kits for detection of a molecule of interest. The present invention is based, at least in part, on the design of nucleic acid oligonucleotides such that they can be used as molecular building blocks which can be assembled (polymerized) to form a dsDNA polymerization product which can be detected and further, can be disassembled (depolymerized) such that the polymerization product is no longer detectable. The invention can be performed multiple times on the same cell population, and is therefore useful for highly sensitive in situ detection of multiple biomarkers.

Abstract: A compound comprising: (a) a drug carrier comprising coumarin-labeled-cysteine tethered mesoporous silica nanoparticles (MSNs) loaded with a pharmaceutically active agent, and (b) a fluorescein isothiocyanate-?-cyclodextrin (FITC-?-CD) covalently linked to said cysteine and blocking the release of said pharmaceutically active agent from said nanoparticles, wherein cleavage of said covalent linkage removes said cyclodextrin and releases said pharmaceutically active agent, and said coumarin and said fluorescin form a donor-acceptor pair so that said drug carrier has a first emission wavelength when the covalent linkage is intact and the cyclodextrin said present and a second emission wavelength after cleavage of said covalent linkage to remove said cyclodextrin and release said pharmaceutically active agent.